Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

HONG KONG (AP) — Asian stocks were mixed Wednesday followed Wall Street’s mostly positive performance ahead of key U.S.

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

With the close of 2024 and the launch of a new year, we can take a moment to look back at what was another eventful, ...

As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...

U.S. stock futures were marginally higher on Monday night after the S&P 500 and Nasdaq Composite notched a second winning day ...

Since pharmaceutical giant Eli ... role in Lilly's current sell-off. First, investors were not pleased with the financial results for the company's diabetes and obesity care drugs -- Mounjaro ...

An estimated 39 million American adults suffer from obstructive sleep apnea, a condition in which the upper airway is blocked while sleeping.

The U.S. Food and Drug Administration ruled Thursday that the shortage of tirzepatide — the active ingredient in Eli Lilly’s (LLY) popular diabetes and weight-loss drugs Mounjaro and Zepbound ...